Additional Information
Book Details
Abstract
Neonatal sepsis contributes significantly to neonatal morbidity and mortality. The incidence of neonatal sepsis as per National Neonatal Perinatal Database (NNPD 2002-2003) is 30 per 1,000 live births among intramural neonates. Among extramural neonates, sepsis accounts for nearly 40% of admissions to the NICU. It accounts for 18% of neonatal mortality among intramural neonates and nearly 40% of mortality among extramural neonates. The incidence and mortality is much higher in VLBW neonates as compared to term neonates.
Neonatal sepsis is a clinical syndrome characterized by systemic signs of infection and accompanied by bacteremia in the first month of life. Once bacteria gains access to the bloodstream, mechanisms are activated by the host to eliminate it. Usually, the bacteria are efficiently cleared by the monocyte macrophage system after opsonization by antibody and complement. Sometimes, however, a systemic inflammatory response syndrome is established and can progress independently of the original infection. In many patients with sepsis, it is difficult to document a bacterial cause. The term "systemic inflammatory response syndrome" includes several stages of infection ranging from sepsis, sepsis syndrome, and early septic shock to refractory septic shock, which can eventuate in multiple organ dysfunction syndrome (MODS) and death.
Prevention of sepsis is probably the best management strategy as far as neonatal sepsis is concerned. Strategies include prevention of early-onset sepsis and prevention of late-onset sepsis. For the former, appropriate obstetric care is the key; for the latter, decreasing interventions, promoting breast feeding, and maintaining proper hand hygiene are essential.
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | Front Cover | ||
Front Matter | ia | ||
Copyright | id | ||
ECAB Clinical Update:Pediatrics | ie | ||
Neonatal Sepsis | if | ||
About the Authors | ig | ||
Contents | ii | ||
ECAB Clinical Update InformationNEONATAL SEPSIS | i | ||
Introduction | 1 | ||
Etiopathogenesis of Neonatal Sepsis and Current Concepts | 3a | ||
ABSTRACT | 3a | ||
KEYWORDS | 3a | ||
Definitions and Terminology | 3a | ||
Current Concepts in Pathophysiology | 5 | ||
Extent of Problem in India | 8 | ||
Neonatal Mortality and Infections: Global Perspective | 8 | ||
Bacteriology | 9 | ||
Organisms Causing Neonatal Meningitis | 9 | ||
Antibiotic Resistance | 10 | ||
Clinical Manifestations | 10 | ||
Evidence of Multiorgan Dysfunction | 13 | ||
Case Studies Etiopathogenesis of Neonatal Sepsis and Current Concepts | 16 | ||
Case Study 1 Progression of Systemic Inflammatory Response Syndrome (SIRS) | 16 | ||
On Examination | 16 | ||
Discussion | 17 | ||
Case Study 2 Meningitis | 17 | ||
On Examination | 17 | ||
Neonatal Sepsis: Diagnostic Issues | 21a | ||
ABSTRACT | 21a | ||
KEYWORDS | 21a | ||
Clinical Diagnosis | 21a | ||
Blood or Body Fluid Culture | 22 | ||
Blood Volume | 23 | ||
Urine Cultures | 23 | ||
Tracheal/Pharyngeal Aspirates | 23 | ||
The Need for Rapid Diagnostic Tests | 24 | ||
Conventional Sepsis Screen | 24 | ||
C-Reactive Protein | 25 | ||
Absolute Neutrophil Count | 25 | ||
Immature to Total Neutrophil Ratio | 26 | ||
Micro-ESR | 27 | ||
Newer Diagnostic Markers | 27 | ||
Other Acute-Phase Reactants | 28 | ||
Procalcitonin: | 28 | ||
Serum Amyloid A: | 28 | ||
Lipopolysaccharide-Binding Protein: | 28 | ||
Cytokines | 29 | ||
Chemokines | 29 | ||
Leukocyte Surface Antigens: | 29 | ||
Molecular Techniques | 30 | ||
Polymerase Chain Reaction | 30 | ||
Lumbar Puncture | 31 | ||
Case Study Neonatal Sepsis: Diagnostic Issues | 34 | ||
Case Scenario | 34 | ||
Management of Neonatal Sepsis | 36a | ||
ABSTRACT | 36a | ||
KEYWORDS | 36a | ||
Choice of Antibiotics on the Basis of Causative Organisms in India | 38 | ||
Antibiotic Cycling and Antibiotic Holiday | 40 | ||
Duration and Frequency of Antibiotics (Tables 2 and 3) | 40 | ||
Adjuvant Therapy in Neonatal Sepsis5-7 | 42 | ||
Neonatal Immunology5 | 42 | ||
Intravenous Immunoglobulin | 43 | ||
IVIG in the Treatment of Suspect or Proven Sepsis:9,10 | 43 | ||
Prophylactic Use of IVIG: | 44 | ||
Recommendation in the Indian Scenario: | 44 | ||
Colony Stimulating Factors | 44 | ||
Rationale: | 44 | ||
Dose and Schedule: | 44 | ||
Recommendation: | 44 | ||
Pentoxifylline13 | 45 | ||
Dose and Schedule: | 45 | ||
Recommendation: | 45 | ||
Activated Protein C | 45 | ||
Exchange Transfusion | 45 | ||
Management of Fungal Infections14-17 | 46 | ||
Prophylaxis with Fluconazole in VLBW Neonates | 48 | ||
Prevention of Sepsis | 48 | ||
Clinical Pearls | 49 | ||
Case Studies Management of Neonatal Sepsis | 50 | ||
Case Study 1 | 50 | ||
History | 50 | ||
Discussion | 50 | ||
Diagnosis | 50 | ||
Investigations | 50 | ||
Case Study 2 | 51 | ||
Evidence-Based Strategies for Prevention of Infection in Nursery | 53a | ||
ABSTRACT | 53a | ||
KEYWORDS | 53a | ||
Administrative Factors | 54 | ||
The Infection Control and Prevention Team | 55 | ||
Surveillance | 55 | ||
Nicu Design | 56 | ||
Category IA | 56 | ||
Category IB | 56 | ||
Category II | 56 | ||
Physical Setup | 56 | ||
Space | 56 | ||
Ventilation | 57 | ||
Scrub Areas | 57 | ||
Airborne Isolation Room(s) | 58 | ||
Prevention and Control of Infections | 58 | ||
Staff Health | 58 | ||
Dress Code | 58 | ||
General Housekeeping | 58 | ||
Neonatal Linen-Clean and Soiled | 59 | ||
Clean Linen | 59 | ||
Soiled Linen | 59 | ||
Environmental Measures | 60 | ||
Guidelines for Disinfection and Sterilization27 | 60 | ||
Surface Disinfection | 61 | ||
Air Disinfection | 62 | ||
Commonly Used Chemical Disinfectants | 62 | ||
Alcohol | 62 | ||
Uses: | 62 | ||
Chlorine and Chlorine Compounds | 62 | ||
Summary | 99 | ||
ECAB Ciinical Update: Pediatrics | 102 | ||
Allergy and Asthma | 102 | ||
Urinary Tract Infections and Anomalies | 103 | ||
Idiopathic Thrombocytopenic Purpura | 103 |